Intellia Therapeutics (NTLA) Net Income towards Common Stockholders (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$192.2 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 24.62% year-over-year to -$192.2 million in Q1 2026; TTM through Mar 2026 was -$625.1 million, a 6.39% increase from a year earlier, with the FY2025 full-year figure at -$1.3 billion, down 4.47% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$192.2 million, down from -$92.3 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for NTLA reached as high as -$92.3 million in Q4 2025 and fell as low as -$348.6 million in Q1 2022.
• Historically, Net Income towards Common Stockholders has averaged -$174.8 million across 5 years, with a median of -$159.4 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders soared 80.49% in 2022 and sank 97.63% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$108.6 million in 2022, then plunged by 50.48% to -$163.4 million in 2023, then advanced by 22.56% to -$126.5 million in 2024, then gained by 27.04% to -$92.3 million in 2025, then sank by 108.23% to -$192.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$192.2 million in Q1 2026, -$92.3 million in Q4 2025, and -$222.4 million in Q3 2025.